Treating serious disease

Medicines for diseases that shorten or threaten lives, such as cystic fibrosis, HIV, cancer and sickle cell disease.

Listed when at least half of its revenue is in this cause

Puts its listed companies on your watchlist. Needs a free account.

BelowBase caseAbove

None of the 2 valued companies trades below its base case. On StockValuer’s numbers, today’s prices already pay for more than the base case expects. A good cause doesn’t make any price a good price.

Listed companies2

At least half of revenue in this cause. Sorted by how much.

Vertex PharmaceuticalsVRTX · Nasdaq

Revenue in treating serious disease

99%
  • TRIKAFTA/KAFTRIO (counted)86%
  • ALYFTREK (counted)7%
  • Other cystic fibrosis medicines (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) (counted)5%
  • CASGEVY (counted)1%
  • JOURNAVX0.5%
  • Other revenues0.3%

Cystic fibrosis medicines and CASGEVY, for sickle cell disease, count. JOURNAVX, a pain medicine, does not.

Price against value

No margin of safety
$515.02
price, off scale
$266.30
base IV/share
Bear $134.94Bull $442.46

Price 93% above base case · price Friday 20th November 2026

Gilead SciencesGILD · Nasdaq

Revenue in treating serious disease

95.4%
  • HIV (counted)70.5%
  • Liver Disease (counted)10.9%
  • Cell Therapy (counted)6.2%
  • Trodelvy (counted)4.7%
  • Veklury (counted)3.1%
  • Other products2.7%

HIV, liver disease, cancer (Cell Therapy and Trodelvy) and COVID-19 (Veklury) count. “Other products” does not.

Price against value

No margin of safety
$166.43
price
$126.08
base IV/share
Bear $67.11Bull $209.09

Price 32% above base case · price Friday 20th November 2026

How a company gets into a cause

Listed when at least half of its revenue is in this cause, by the revenue lines in its latest 10-K. A name, a mission or a logo never counts. How causes work

What owning a share does

Buying a share on an exchange pays the seller, not the company. What you get is a part of the business and a vote at its annual meeting.

StockValuer is an educational analysis tool. Every reader sees the same causes, companies and figures. Nothing here is a recommendation to buy, sell or hold any security, or a judgement that a company does good.